Editas Medicine said Thursday afternoon it will lay off 65% of its staff — around 180 employees — as it shelves its lead gene-editing program for sickle cell disease and shifts focus.
The Cambridge, Mass.-based company on Thursday said it will now focus on in vivo Crispr-edited medicines based on its researchers recent scientific progress in multiple tissues. At the same time, it ...